UBUnnur Bjornsdottir

Unnur Bjornsdottir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Unnur Bjornsdottir has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Altraja

    Department of Pulmonology University of Tartu and Lung Clinic, Tartu University Hospital Tartu Estonia

    1 shared publication
  • Andrew N. Menzies‐Gow

    Royal Brompton & Harefield Hospitals London UK

    1 shared publication
  • Andrey S. Belevskiy

    Department of Pulmonology N.I. Pirogov Russian State National Research Medical University Moscow Russian Federation

    1 shared publication
  • Andriana Papaioannou

    2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece

    1 shared publication
  • Anna von Bulow

    Respiratory Research Unit Bispebjerg University Hospital Copenhagen Denmark

    1 shared publication
  • Anthony Newell

    Observational and Pragmatic Research Institute Singapore Singapore

    1 shared publication

Latest Publications

  • Open Access

    Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both

    by Paul E. Pfeffer, Nasloon Ali, Ruth Murray, Charlotte Ulrik, Trung N. Tran, Jorge Maspero, Matthew Peters, George C. Christoff, Mohsen Sadatsafavi, Carlos A. Torres‐Duque, et al.

    Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti‐IgE and anti‐IL5/5R and to compare the effectiveness of both classes of treatment in real life.Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti‐IgE and anti‐IL5/5R. The effectiveness of anti‐IgE and anti‐IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long‐term‐oral corticosteroid (LTOCS) use, asthma‐related emergency room (ER) attendance, and hospital admissions.Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti‐IL5/5R group and 38.7% in the anti‐IgE group. Patients treated with anti‐IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti‐IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti‐IL5/5R experienced fewer asthma‐related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43).Conclusions: In real life, both anti‐IgE and anti‐IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti‐IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.


  • Inhibition of eosinophil density change and leukotriene C4 generation by nedocromil sodium

    by Julie B. Sedgwick, Unnur Bjornsdottir, Kristen M. Geiger, William W. Busse